Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
- Conditions
- Mullerian Mixed Tumor of Ovary
- Registration Number
- NCT02090127
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Brief Summary
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
- Detailed Description
This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Per original P05538 protocol
Exclusion Criteria
- Per original P05538 protocol
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
START
🇺🇸San Antonio, Texas, United States